Argos Therapeutics Inc. (NASDAQ:ARGS) traded up 2.7% during trading on Friday . The stock traded as high as $6.19 and last traded at $6.15, with a volume of 115,123 shares. The stock had previously closed at $5.99.

Several equities research analysts have commented on the stock. Zacks Investment Research cut shares of Argos Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $11.00 price target on shares of Argos Therapeutics in a research report on Monday, June 20th. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of Argos Therapeutics in a report on Friday, June 17th. FBR & Co restated a “buy” rating on shares of Argos Therapeutics in a report on Tuesday, June 14th. Finally, Roth Capital boosted their price objective on Argos Therapeutics from $11.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, April 19th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $11.84.

The firm’s 50-day moving average is $6.16 and its 200-day moving average is $5.38. The firm’s market cap is $159.23 million.

Argos Therapeutics (NASDAQ:ARGS) last announced its earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.01. Equities analysts forecast that Argos Therapeutics Inc. will post ($1.74) earnings per share for the current year.

Argos Therapeutics, Inc (Argos) is a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s advanced product candidate is AGS-003, which the Company is developing for the treatment of metastatic renal cell carcinoma (mRCC) and other cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.